TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35172981
Drug: CALM (Managing
Approvals — FDA: no, EMA: no, PMDA: no
Description: CALM (Managing Cancer and Living Meaningfully) therapy
Study: 35472303
Drug: Screening for
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening for AF using a 2-week single-lead electrocardiographic patch monitor
Study: 34097044
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of BNT162b2 vaccine
Study: 34543417
Drug: Ledipasvir/Sofosbuvir treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir/Sofosbuvir treatment (12-week course)
Study: 34543417
Drug: Low adherence
Normalized name: dressing,low adherence and wound contact materials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low adherence (taking <90% of doses)
Study: 34543417
Drug: High adherence
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High adherence (taking ≥90% of doses)
Study: 34292792
Drug: T300 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: T300 + D (tremelimumab 300 mg plus durvalumab 1,500 mg followed by durvalumab 1,500 mg once every 4 weeks)
Study: 34292792
Drug: Durvalumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab monotherapy (1,500 mg once every 4 weeks)
Study: 34292792
Drug: Tremelimumab monotherapy
Normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab monotherapy (750 mg once every 4 weeks for seven doses, then once every 12 weeks)
Study: 34292792
Drug: T75 +
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: T75 + D (tremelimumab 75 mg once every 4 weeks plus durvalumab 1,500 mg once every 4 weeks for four doses, then durvalumab 1,500 mg once every 4 weeks)
Study: 35692047
Drug: Partial brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial brain radiotherapy (RT) followed by procarbazine, lomustine, and vincristine (PCV) chemotherapy (RT-PCV)
Study: 34210341
Drug: Metacognitive Remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metacognitive Remediation Therapy (MCR)
Study: 35025539
Drug: Supportive-Expressive Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-Expressive Therapy (SET)
Study: 34404446
Drug: Combined physical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined physical and internet‐delivered psychological intervention (psychologically informed physical treatments)
Study: 34273498
Drug: Add-on dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on dry powder inhalation (DPI) of combined anti-TB therapy (isoniazid 5 mg, rifampicin 2 mg, pyrazinamide 16 mg, levofloxacin 2 mg)
Study: 34273498
Drug: Add-on dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on dry powder inhalation (DPI) of combined anti-TB therapy
Study: 32701597
Drug: Sertraline (SSRI)
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline (SSRI)
Study: 35758850
Drug: SpikoGen® vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SpikoGen® vaccine
Study: 35574009
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart injected with a needle-free syringe into the abdomen
Study: 35574009
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart injected with a needle-free syringe into the upper arm
Study: 35574009
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart injected with a needle-free syringe into the thigh
Study: 34082633
Drug: Demographic factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demographic factors (drug-use-related disorders)
Study: 36434514
Drug: ZYN002 (cannabidiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZYN002 (cannabidiol transdermal gel) 250 mg or 500 mg daily for 12 weeks
Study: 35050705
Drug: App-based visual-acoustic
Approvals — FDA: no, EMA: no, PMDA: no
Description: App-based visual-acoustic biofeedback using Speech Therapist's App for /r/ Treatment
Study: 35050705
Drug: Nonbiofeedback treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonbiofeedback treatment using Speech Therapist's App for /r/ Treatment
Study: 38630471
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of treatment success rates
Study: 33191408
Drug: Belotecan (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belotecan (0.5 mg/m2)
Study: 33191408
Drug: Topotecan (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan (1.5 mg/m2)
Study: 33203854
Drug: Lapatinib (L;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (L; N = 36)
Study: 32803294
Drug: N-acetylcysteine inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine inhalation therapy (2400 mg daily for 8 weeks)
Study: 34325680
Drug: Severe anaemia
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe anaemia (Hb 4-6 g/dL and no severity features), no transfusion during initial admission
Study: 34325680
Drug: Missing ≥1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Missing ≥1 trial medication dose
Study: 35311593
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg shrimp oil once per day for eight weeks
Study: 35598698
Drug: Time to
Normalized name: Overtime Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time to 50% daily calorie intake
Study: 32919068
Drug: High-dose eplerenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose eplerenone (100-200 mg)
Study: 32664953
Drug: Restriction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restriction of enteral feed volume to 120 ml/kg/day for 12 hours
Study: 35918311
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g of dried psilocybin mushrooms
Study: 35998623
Drug: SOBERANA 02
Normalized name: Soberana 01
DrugBank: FINLAY-FR-1 (DB16524)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOBERANA 02 (two doses) + SOBERANA Plus (third dose)
Study: 34310011
Drug: ORMD-0801 (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORMD-0801 (16 or 24 mg, once daily at bedtime for 28 days)
Study: 34189703
Drug: GSK2586881 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2586881 0.8 mg/kg
Study: 34783100
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) prescribed if blood eosinophils ≥3%
Study: 34783100
Drug: Targeted antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted antibiotics for airway bacterial infection
Study: 32929822
Drug: Pharmacist-led, patient-oriented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led, patient-oriented education and medication management intervention
Study: 36509053
Drug: Azithromycin (single-dose)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin (single-dose)
Study: 33849913
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (2,000 IU orally daily for 1 year)
Study: 35680252
Drug: Cannabis products
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis products added to a behavioural pain management and prescription opioid taper support programme
Study: 36395262
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (GP)
Study: 36252745
Drug: Duloxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (60 mg daily from the day of surgery to postoperative day 6)
Study: 32100500
Drug: Wheat-grain moxibustion
Normalized name: Light wheat grain
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat-grain moxibustion at Yinbai (SP 1), performed once a day with an interval of 1 day between two 3-day treatments.
Study: 32100500
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of dydrogesterone tablet, 10 mg twice a day.
Study: 35180298
Drug: Acetaminophen (500mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (500mg or 1000mg 6-hourly for 72 hours)
Study: 35569002
Drug: Oral Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Misoprostol (OM) 50 µg four hourly for 48 hours
Study: 34052421
Drug: Ultrasonic scaling
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic scaling + oral hygiene instructions
Study: 34052421
Drug: Ultrasonic scaling/oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic scaling/oral hygiene instructions + aPDT
Study: 32558469
Drug: Systematic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic treatment with rifampin, isoniazid, ethambutol, and pyrazinamide daily for 2 months, followed by rifampin and isoniazid daily for 4 months.
Study: 32558469
Drug: Guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided treatment (screening with Xpert MTB/RIF test, urinary lipoarabinomannan test, and chest radiography).
Study: 32558469
Drug: Systematic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic treatment
Study: 35969436
Drug: Reminder group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminder group (daily reminders via WeChat)
Study: 34533505
Drug: Machine Learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine Learning (ML) algorithm for predicting unplanned subsequent surgery after intramedullary nailing (IMN) for TSFs
Study: 35945566
Drug: IV alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV alteplase (5mg) followed by continuous IV infusion of m‐proUK (40 mg/h during 60 min)
Study: 35945566
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care with alteplase (0.9 mg/kg)
Study: 33805908
Drug: Tetrodotoxin (TTX)
Normalized name: Tetrodotoxin
DrugBank: Tetrodotoxin (DB05232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrodotoxin (TTX) 30 µg BID
Study: 35549912
Drug: HIPEC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIPEC with high-dose mytomicin-C (35 mg/m2)
Study: 35549912
Drug: Personalized systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized systemic chemotherapy (both arms)
Study: 36209381
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of triamcinolone acetonide after fractional CO2 laser treatment
Study: 36209381
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of triamcinolone acetonide after microneedling (MN) treatment
Study: 34562648
Drug: 5-Aminolaevulinic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Aminolaevulinic Acid Photodynamic Therapy (ALA PDT)
Study: 35863669
Drug: Prednisolone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (0.5 mg/kg/d, maximum 40 mg/d, for 14 ± 2 days)
Study: 34294595
Drug: Durvalumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (10 mg/kg intravenously every 2 weeks for 12 months)
Study: 32967873
Drug: Intravenous haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous haloperidol 2.5 mg every 8 hours, titrated to a maximum of 5 mg every 8 hours until delirium resolution or ICU discharge.
Study: 34181750
Drug: Budesonide (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (9 mg/day for 10 weeks)
Study: 34723163
Drug: C21 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: C21 (100 mg bid for 7 days)
Study: 33040002
Drug: Febuxostat (hyperuricaemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (hyperuricaemia treatment)
Study: 32598683
Drug: NSAIDs +
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NSAIDs + Injectran (Chondroitin sulfate) 200 mg I.M. every other day No. 25
Study: 32598683
Drug: NSAIDs +
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NSAIDs + Fermatron 1% 2 ml I.A. with an interval of 7 days No. 3
Study: 32598683
Drug: NSAIDs +
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NSAIDs + Injectran 200 mg I.M. every other day No. 25 + Fermatron 1% 2 ml I.A. with an interval of 7 days No. 3
Study: 35157497
Drug: Activity monitoring
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activity monitoring with triage visits triggered by a 20% decrease in daily steps or 20% increase in heart rate.
Study: 33582664
Drug: Colchicine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (2 mg oral bolus followed by 0.5 mg b.i.d. for 5 days)
Study: 36163722
Drug: Curcumin 500
Normalized name: curcumin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin 500 mg per oral capsule twice daily for 1 month plus nutritional standard of care (SOC)
Study: 36338456
Drug: Systemic decolonization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic decolonization (topical chlorhexidine gluconate, intranasal mupirocin, oral rifampin, and oral doxycycline)
Study: 36338456
Drug: Standard decolonization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard decolonization (topical chlorhexidine gluconate and intranasal mupirocin)
Study: 34371442
Drug: Maintenance of
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance of androgen deprivation therapy (ADT)
Study: 34371442
Drug: Intermittent docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent docetaxel administration
Study: 34371442
Drug: Suspension of
Normalized name: Suspension of heat killed (autoclaved) Mycobacterium w
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension of androgen deprivation therapy (ADT)
Study: 32438639
Drug: Concord grape
Normalized name: Concord Grape
DrugBank: Concord grape (DB10875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concord grape juice (CGJ), 16 ounces daily for 24 weeks
Study: 36404282
Drug: Adapted group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted group cognitive-behavioral therapy (CBT) program
Study: 32075665
Drug: Twice-weekly haemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly haemodialysis sessions
Study: 32075665
Drug: Thrice-weekly haemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly haemodialysis regimen
Study: 35771894
Drug: Ever using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ever using drugs of addiction
Study: 34931773
Drug: 3D-printed implant
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D-printed implant overdentures
Study: 34931773
Drug: Conventional implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional implant overdentures
Study: 35486418
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy for insomnia (ICBT‐i)
Study: 33826992
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (writing about daily activities)
Study: 35842062
Drug: Blood Flow
Normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood Flow Restriction (BFR) therapy with pneumatic cuff set to 80% limb occlusion pressure, performed 5 days per week for two weeks
Study: 34834540
Drug: Standard escitalopram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard escitalopram dosing
Study: 34834540
Drug: Dosing based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing based on validated CYP2C19 phenotypes for escitalopram metabolism
Study: 36011930
Drug: HEUR-L (heuristic
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEUR-L (heuristic learning)
Study: 36011930
Drug: HEUR-L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEUR-L
Study: 36011930
Drug: HEUR-L and
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEUR-L and PRES-T
Study: 32533264
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of strategic mini-implants
Study: 32533264
Drug: Delayed loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed loading of strategic mini-implants
Study: 36092959
Drug: Antimicrobial step‐down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial step‐down therapy (imipenem/cilastatin)
Study: 36092959
Drug: Conventional antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antimicrobial therapy (sulbactam plus cefoperazone)
Study: 39586038
Drug: Alkylating agents
Normalized name: ALKYLATING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkylating agents (ALKY)
Study: 35251715
Drug: Maze control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maze control training in addition to selected conventional physical therapy
Study: 36375173
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg duloxetine
Study: 32888454
Drug: Carboplatin plus
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin plus etoposide (six cycles of intravenous carboplatin [AUC 5 mg/mL per min] on day 1 plus intravenous etoposide [100 mg/m2 from day 1 to day 3])
Study: 32888454
Drug: Topotecan (2.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan (2.3 mg/m2 from day 1 to day 5, for six cycles)
Study: 32986176
Drug: Apixaban 5
Normalized name: apixaban 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 5 mg/12 h or 2.5 mg/12 h (after dose adjustment or in high-risk patients)
Study: 32986176
Drug: DAPT with
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT with aspirin and clopidogrel
Study: 33228726
Drug: losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: losartan potassium plus Keluoxin capsule (KLX)
Study: 32925743
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) 1000 mg in 100 mL normal saline, administered intravenously over 20 minutes before skin incision
Study: 39222701
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) - aspirin plus clopidogrel
Study: 33678522
Drug: Atezolizumab 1200
Normalized name: atezolizumab 1200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1200 mg IV plus Bevacizumab 15 mg/kg IV every 3 weeks
Study: 39532375
Drug: Atezolizumab monotherapy
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab monotherapy
Study: 34251103
Drug: Longidaza (rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longidaza (rectal suppositories of 3000 IU)
Study: 34251103
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard postoperative therapy with tamsulosin and fluoroquinolone)
Study: 616886749
Drug: Compound azintamide
Normalized name: Azintamide
DrugBank: Azintamide (DB13992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound azintamide enteric‐coated tablets
Study: 616886749
Drug: Compound digestive
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound digestive enzyme capsules
Study: 33369909
Drug: Leu/Met/Sil 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leu/Met/Sil 1.0 in participants with baseline insulin ≥12mU/L
Study: 34789403
Drug: ap1gen (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: ap1gen (low-dose recombinant pertussis-only vaccine containing 1 μg PTgen and 1 μg FHA)
Study: 34789403
Drug: Tdap1gen (tetanus,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap1gen (tetanus, reduced-dose diphtheria combined to ap1gen)
Study: 34789403
Drug: Tdap2gen (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap2gen (combined to recombinant pertussis containing 2 μg PTgen and 5 μg FHA)
Study: 34789403
Drug: TdaP5gen (licensed
Approvals — FDA: no, EMA: no, PMDA: no
Description: TdaP5gen (licensed recombinant TdaP vaccine containing 5 μg PTgen and 5 μg FHA)
Study: 34789403
Drug: Tdap8chem (licensed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap8chem (licensed Tdap vaccine containing 8 μg of chemically inactivated pertussis toxoid, 8 μg FHA, and 2.5 μg pertactin)
Study: 35343648
Drug: Cisplatin 30
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 30 mg/m2 once-a-week with radiotherapy
Study: 35343648
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 once every-3-weeks with radiotherapy
Study: 34059488
Drug: lenalidomide treatment
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lenalidomide treatment
Study: 32532291
Drug: Enadenotucirev (EnAd)
Normalized name: Enadenotucirev
DrugBank: Enadenotucirev (DB14873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enadenotucirev (EnAd) in combination with chemoradiotherapy
Study: 34453840
Drug: Drug (pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug (pharmacological rate control)
Study: 35119113
Drug: Solution-focused psychoeducation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution-focused psychoeducation (SFP)
Study: 35119113
Drug: Childbirth preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Childbirth preparation training (CPT)
Study: 32491964
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) (G2)